Summit Therapeutics SMMT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $132.62M+159% | $147.29M+187% | $131.1M+248% | $208.02M+575% | $51.27M+66.1% | ||
| $62.59M+302% | $77.63M+445% | $103.12M+399% | $360.42M+2,509% | $15.59M+35.3% | ||
| $195.21M+192% | $224.93M+243% | $234.21M+301% | $568.44M+853% | $66.85M+57.7% | ||
| $5.79M+47.0% | $5.75M+30.2% | $2.42M-47.2% | $2.73M+16.9% | $3.94M+93.3% | ||
| -$189.42M-201% | -$219.17M-258% | -$231.79M-312% | -$565.71M-837% | -$62.91M-44.7% | ||
| -$0.24-167% | -$0.28-211% | -$0.31-287% | -$0.76-744% | -$0.09-50.0% | ||
| -$0.24-167% | -$0.28-211% | -$0.31-287% | -$0.76-744% | -$0.09-50.0% | ||
| 775.5M+5.1% | 747.7M+4.1% | 743.4M+2.3% | 742.6M+4.9% | 738.1M+5.2% | ||
| 775.5M+5.1% | 747.7M+4.1% | 743.4M+2.3% | 742.6M+4.9% | 738.1M+5.2% | ||
| -$189.52M-200% | -$219M-258% | -$231.75M-313% | -$565.9M-838% | -$63.19M-45.4% | ||
| $44K+76.0% | $42K+90.9% | $42K+110% | $37K+85.0% | $25K-7.4% | ||
| -$19K-150% | —— | $22K-80.7% | $61K— | $38K+206% | ||
| $6.8M+1,811% | —— | —— | $17.93M— | $356K-90.4% | ||
| $12.22M+658% | $5.53M+143% | $945K-84.0% | $4.84M-18.4% | $1.61M+172% | ||
| -$7.85M-3.5% | $3.96M-2.1% | —— | —— | -$7.59M-1,352% | ||
| $3.8M-50.5% | $573.82M— | $33.81M-83.4% | $2.22M-98.9% | $7.68M+1,483% | ||
| -$238K-100% | -$485.16M— | -$71K+99.9% | $150.81M+175% | $160.11M+706% | ||
| -$122.29M-99.9% | -$101.94M-109% | -$93.08M-207% | -$66.74M-102% | -$61.17M-103% | ||
| $84K+158% | -$36K-115% | $43K+128% | -$189K-305% | -$145K-1,108% | ||
| -$176K-32.3% | $205K— | $0-100% | $0+100% | -$133K-1,309% | ||
| $245K-41.9% | $164K+1,071% | $71K+22.4% | $0-100% | $422K+10,450% | ||
| $177.29M— | $484.99M+224% | $0-100% | $0-100% | $0-100% | ||
| $3.8M+88.1% | $1.02M+106% | $2.05M+24.6% | $565K+409% | $2.02M+316% | ||
| $72.79M+556% | $111.78M+915% | $130.76M+575% | $478.78M+4,218% | $11.1M+16.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Summit Therapeutics profitable?
- Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.
- What is Summit Therapeutics's earnings per share?
- Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.
- Where does Summit Therapeutics's income statement data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.